Cancer Drugs Fund requires further reform
Reliance on “real world” observational data undermines evidence base for clinical practice.
Main Authors: | Grieve, R, Abrams, K, Claxton, K, Goldacre, B, James, N, Nicholl, J, Parmar, M, Parker, C, Sekhon, J, Smeeth, L, Spiegelhalter, D, Sculpher, M |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
BMJ Publishing Group
2016
|
Registos relacionados
-
Huang Shu Yin funded for further study
Por: Kwong Wah, Yit Poh
Publicado em: (2017) -
Huang Shu Yin Funded For Further Study
Por: Kwong Wah, Yit Poh
Publicado em: (2017) -
MRE in NAFLD: promising but further validation is required
Por: Ryan, J, et al.
Publicado em: (2018) -
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
Por: Morrell, L, et al.
Publicado em: (2018) -
Bladder cancer: issues requiring further research
Por: I. A. Rozhkov, et al.
Publicado em: (2024-09-01)